Erratum: TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract (Apoptosis DOI: 10.1007/s10495-006-0492-z);TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract

Apoptosis

Volumn 12, Issue 1, 2007, Pages 73-85

  Sadarangani, Anil ^a   Kato, Sumie ^a   Espinoza, Natalia ^a   Lange, Soledad ^a   Llados, Carmen ^a   Espinosa, Marisol ^a   Villalón, Manuel ^a   Lipkowitz, Stanley ^b   Cuello, Mauricio ^a   Owen, Gareth I ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervix; Endometrium; Fallopian; Ovarian cancer

Indexed keywords

CASPASE 8 INHIBITOR; CASPASE 9 INHIBITOR; DEATH RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CANCER; ENZYME INHIBITION; FEMALE; FEMALE GENITAL SYSTEM; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; KILLER CELL; OVARY; PRIORITY JOURNAL; PROTEIN ANALYSIS; UTERINE CERVIX; UTERINE TUBE;

EID: 33845727452     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-0713-5     Document Type: Erratum

References (50)

1. Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A (1999) Control of apoptosis signalling by Apo2 ligand. Recent Prog Horm Res 54:225-234
2. Gibson SB (2004) Epidermal growth factor and TRAIL interactions in epithelial-derived cells. Vitam Horm 67:207-227
3. Wajant H, Gerspach J, Pfizenmaier K (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16:55-76
4. de Thonel A, Eriksson JE (2005) Regulation of death receptors-Relevance in cancer therapies. Toxicol Appl Pharmaco 207:123-132
5. Ling J, Herbst RS, Mendelson DS et al (2006) Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma Journal of Clinical Oncology (Meeting Abstracts); ASCO Annual Meeting Proceedings Part I 24: 3047
6. Kanzler S, Trarbach T, Heinemann V et al (2005) Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC). ECCO 13 - the European Cancer Conference, Abstract 630
7. Bonomi P, Greco FA (2005). Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent non-small cell lung cancer. 11th World Conference on Lung Cancer: Abstract 1851
8. Sheridan JP, Marsters SA, Pitti RM et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-21
9. Baetu TM, Hiscott J (2002) On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13:199-207
10. Cuello M, Ettenberg SA, Clark AS et al (2001) Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61:4892-4900
11. Vignati S, Codegoni A, Polato F, Broggini M (2002) Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 38(1):177-183
12. Leverkus M, Neumann M, Mengling T et al (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553-559
13. Roth W, Isenmann S, Naumann U et al (1999) Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 265:479-483
14. Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
15. Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
16. Kato S, Pinto M, Carvajal A et al (2005) Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost 94:444-453
17. Auersperg N, Siemens CH, Myrdal SE (1984) Human ovarian surface epithelium in primary culture. In Vitro 20:743-755
18. Verdugo P, Langley L, Aitken ML, Villalon M (1990) Development of an in vitro model of primate cervical goblet cells. Biorheology 27:465-470
19. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K (1985) Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 37:1103-1111
20. Kuramoto H (1972) Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet Gynaecol Jpn 19:47-58
21. Louie KG, Behrens BC, Kinsella TJ et al (1985) Radiation survival parameters of antineoplastic drug-sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110-2115
22. Eagle H (1955) Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med 89:362-364
23. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S (2001) Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.Gynecol Oncol 81:380-390
24. KeaneMM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791-4798
25. Li L, Heldin NE, Grawe J, Ulmsten U, Fu X (2004) Induction of apoptosis or necrosis in human endometrial carcinoma cells by 2-methoxyestradiol. Anticancer Res 24:3983-3990
26. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
27. Thigpen T, Vance RB, Khansur T (1995) The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cerviz. Semin Oncol 22:67-75
28. Dolcet X, Llobet D, Pallares J et al (2005) FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 85:885-894
29. Horak P, Pils D, Haller G et al (2005) Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3:335-343
30. Li CM, Peng ZL, Yang KX (2005) The expression of TRAIL, TRAIL-R (DR4, DcR1) and Fas-L in patients with ovarian cancer Sichuan Da Xue Xue Bao Yi Xue Ban 36:341-343
31. Kelley RF, Totpal K, Lindstrom SH et al (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205-2212
32. Vincent H, Claire PP, Marion T et al (2006) Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 66:987-995
33. Reesink-Peters N, Hougardy BM, Van Den Heuvel FA et al (2005) Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96:705-713
34. Lelle RJ, Talavera F, Gretz et al (1993) Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer 72:519-525
35. Yaginuma Y, Westphal H (1991) Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 51: 6506-6509
36. Matsushima-Nishiu M, Unoki M, Ono K et al (2001) Growth and gene expression profile analysis of endometrial cancer cell lines expressing exogenous PTEN. Cancer Res 61:3741-3749
37. Lilja JF, Wu D, Reynolds RK et al (2001) Growth suppression activity of the PTEN tumor suppressor gene in human endometrial cancer cells. Anticancer Res 21:1969-1974
38. Boyd J, Risinger JI (1991) Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. Mol Carcinog 4:189-195
39. Nesterov A, Lu X, Johnson M et al (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276:10767-10774
40. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG (2003) Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278:33753-33762
41. Keane MM, Rubinstein Y, Cuello M et al (2000) Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 64:211-219
42. LeBlanc H, Lawrence D, Varfolomeev E et al (2002) Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274-281
43. Sharp DA, Lawrence DA, Ashkenazi A (2005) Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280:19401-19409
44. Leverkus M, Neumann M, Mengling T et al (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553-559
45. Kumar SR, Singh J, Xia G et al (2006) Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169:279-293.
46. Jo M, Kim TH, Seol DW (2000) Apoptosis induced in normal hepatocytes by tumor necrosis factor-realted apoptosis-inducing ligand. Nat Med 6:564-567
47. Nitsch R, Bechmann I, Deisz RA (2000) Human brain-cell death induced by tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL). Lancet 356:827-828
48. Lawrence D, Shahrokh Z, Marsters S (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385
49. Qin J, Chaturvedi V, Bonish B, Nickoloff BJ (2001) Avoiding premature apoptosis of normal epithelial cells. Nat Med 7:385-386
50. Cuello M, Coats AO, Darko I et al (2004) N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 11(5):527-541